Several ongoing trials are currently evaluating the therapeutic efficacy of several anti-PD-L1 antibodies, alone or in combination with anti-CTLA4 or anti-PD1, for the treatment of NSCLC and SCLC, and they are reported in Supplementary Table S2 [245,246]. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.